Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Volinanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.83 |
| ▸ | HTR7 | P34969 | 5/20 | 0.82 |
| ▸ | HTR1D | P28221 | 4/20 | 0.82 |
| ▸ | DRD4 | P21917 | 3/20 | 0.82 |
| ▸ | HRH2 | P25021 | 3/20 | 0.82 |
| ▸ | HTR1B | P28222 | 3/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.82 |
| ▸ | HTR6 | P50406 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Volinanserin SCHEMBL30543449 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL4227186 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL29356737 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL13701277 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL675164 | 1.00 | HTR2B (1.00) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL29899671 | 0.99 | HTR2B (0.98) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL8008450 | 0.95 | HTR2B (0.90) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL8008033 | 0.94 | HTR2B (0.89) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL22118439 | 0.94 | HTR2B (0.89) | HTR2BHTR2AHTR2CDRD1HRH1 | |
| Volinanserin SCHEMBL22118455 | 0.94 | HTR2B (0.89) | HTR2BHTR2AHTR2CDRD1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | claimed |
| EP-1362589-B1 | Use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol for the treatment of sleep disorders | AVENTIS PHARMA INC (US) | 2009-07-15 | — | — | EP | claimed |
| JP-4165906-B2 | — | — | 2008-10-15 | — | — | JP | claimed |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | claimed |
| EP-1289527-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL OR ITS PRODRUG TO TREAT DEMENTIA OR COGNITIVE IMPAIRMENT | AVENTIS PHARMA INC (US) | 2008-03-26 | — | — | EP | claimed |
| EP-1192134-B1 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | AVENTIS PHARMA INC (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1736469-A2 | Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol | Aventis Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1202967-B1 | SULFURIC ACID MONO-[3-({1-[2-(4-FLUORO-PHENYL)-ETHYL]-PIPERIDIN-4-YL}-HYDROXY-METHYL)-2-METHOXY-PHENYL]ESTER | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-7132433-B2 | Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of behavioral or psychological symptoms associated with a disease | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | claimed |
| EP-0796619-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders | MERRELL PHARMACEUTICALS INC. (US) | 1997-09-24 | — | — | EP | claimed |
| US-5618824-A | ADMINISTERING N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-08 | — | — | US | claimed |
| EP-0749309-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT 2? ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-27 | — | — | EP | claimed |
| US-5561144-A | TREATMENT OF SCHIZOPHRENIA | MERRELL PHARMACEUTICALS INC. (US) | 1996-10-01 | — | — | US | claimed |
| WO-1995024194-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT2 ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-09-14 | — | — | WO | claimed |
| EP-0531410-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMA (US) | 1994-11-30 | — | — | EP | claimed |
| EP-0531410-A4 | (+)--G(A)-(2,3-DIMETHOXYPHENYL)-1- 2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | — | 1993-05-26 | — | — | EP | claimed |
| EP-0531410-A1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL. | MERRELL DOW PHARMA (US) | 1993-03-17 | — | — | EP | claimed |
| US-5134149-A | Serotonin antagonist | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-28 | — | — | US | claimed |
| WO-1991018602-A1 | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | HTR2A 1477/4885HTR2B 1312/4885HTR2C 1273/4885 |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | HCRTR2, OPRD1, HCRTR1 | HTR2A 47/4885HTR2B 87/4885HTR2C 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.